Metraipolis › archive › dc_ead5ab7db785
Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments — Europe PMC PMID:41228373
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41228373
- DOI
- 10.3390/cancers17213582
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T18:23:03.885Z
- SHA-256 of the archived text
f6f41f426e8ea3cf0fba42db5b614e60d8f22e93c3adcb5ab6ee40823f373d2a- Stable URL of this page
https://metraipolis.com/documento/dc_ead5ab7db785
How to cite
Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments — Europe PMC PMID:41228373 — Europe PMC (en), https://europepmc.org/article/MED/41228373 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ead5ab7db785 (Metraipolis archive dc_ead5ab7db785, sha256 f6f41f426e8ea3cf0fba42db5b614e60d8f22e93c3adcb5ab6ee40823f373d2a)
BibTeX
@misc{dcead5ab7db785,
title = {Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments — Europe PMC PMID:41228373},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41228373},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ead5ab7db785; sha256 f6f41f426e8ea3cf0fba42db5b614e60d8f22e93c3adcb5ab6ee40823f373d2a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41228373. Agents can read the archived copy with the MCP tool read_document.